Mani Foroohar
Stock Analyst at Leerink Partners
(2.24)
# 2,653
Out of 4,876 analysts
164
Total ratings
48.31%
Success rate
-7.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mani Foroohar
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCKT Rocket Pharmaceuticals | Downgrades: Market Perform | $37 → $8 | $2.58 | +210.08% | 11 | May 28, 2025 | |
| LXEO Lexeo Therapeutics | Maintains: Outperform | $19 → $18 | $4.17 | +331.65% | 3 | Mar 24, 2025 | |
| RXRX Recursion Pharmaceuticals | Maintains: Market Perform | $7 → $6 | $5.33 | +12.57% | 8 | Feb 28, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Outperform | $31 → $27 | $4.07 | +563.39% | 9 | Jan 13, 2025 | |
| NGNE Neurogene | Maintains: Outperform | $45 → $72 | $16.72 | +330.62% | 2 | Nov 12, 2024 | |
| CAMP Camp4 Therapeutics | Initiates: Outperform | $17 | $1.53 | +1,011.11% | 1 | Nov 5, 2024 | |
| MIRM Mirum Pharmaceuticals | Maintains: Outperform | $47 → $49 | $50.52 | -3.01% | 11 | Oct 17, 2024 | |
| BBIO BridgeBio Pharma | Maintains: Outperform | $47 → $46 | $44.95 | +2.34% | 15 | Oct 17, 2024 | |
| WVE Wave Life Sciences | Maintains: Outperform | $20 → $22 | $6.95 | +216.55% | 6 | Oct 16, 2024 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $53 → $62 | $39.78 | +55.86% | 15 | Jul 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $13 | $12.35 | +5.26% | 1 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $29 | $20.40 | +42.16% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $230 | $17.25 | +1,233.33% | 1 | Jun 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $12 → $4 | $5.35 | -25.16% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $8.75 | - | 10 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $31 | $3.68 | +742.39% | 1 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $0.66 | +968.54% | 1 | Nov 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $40 | $16.10 | +148.52% | 12 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $111 → $93 | $27.75 | +235.20% | 17 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $86 → $84 | $9.74 | +762.87% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $6 → $7 | $2.17 | +222.58% | 4 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $77 | $17.25 | +346.38% | 2 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $144 → $143 | $316.25 | -54.78% | 11 | Jan 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $6 | $5.82 | +3.09% | 5 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $76 | $46.66 | +62.90% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $1.35 | +2,418.52% | 4 | May 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $50 → $20 | $2.49 | +703.21% | 6 | Jul 23, 2021 |
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Market Perform
Price Target: $37 → $8
Current: $2.58
Upside: +210.08%
Lexeo Therapeutics
Mar 24, 2025
Maintains: Outperform
Price Target: $19 → $18
Current: $4.17
Upside: +331.65%
Recursion Pharmaceuticals
Feb 28, 2025
Maintains: Market Perform
Price Target: $7 → $6
Current: $5.33
Upside: +12.57%
4D Molecular Therapeutics
Jan 13, 2025
Maintains: Outperform
Price Target: $31 → $27
Current: $4.07
Upside: +563.39%
Neurogene
Nov 12, 2024
Maintains: Outperform
Price Target: $45 → $72
Current: $16.72
Upside: +330.62%
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: $17
Current: $1.53
Upside: +1,011.11%
Mirum Pharmaceuticals
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $49
Current: $50.52
Upside: -3.01%
BridgeBio Pharma
Oct 17, 2024
Maintains: Outperform
Price Target: $47 → $46
Current: $44.95
Upside: +2.34%
Wave Life Sciences
Oct 16, 2024
Maintains: Outperform
Price Target: $20 → $22
Current: $6.95
Upside: +216.55%
Ionis Pharmaceuticals
Jul 24, 2024
Upgrades: Outperform
Price Target: $53 → $62
Current: $39.78
Upside: +55.86%
Jul 22, 2024
Initiates: Outperform
Price Target: $13
Current: $12.35
Upside: +5.26%
Jul 2, 2024
Initiates: Outperform
Price Target: $29
Current: $20.40
Upside: +42.16%
Jun 24, 2024
Maintains: Outperform
Price Target: $165 → $230
Current: $17.25
Upside: +1,233.33%
Apr 25, 2024
Downgrades: Market Perform
Price Target: $12 → $4
Current: $5.35
Upside: -25.16%
Mar 6, 2024
Upgrades: Outperform
Price Target: n/a
Current: $8.75
Upside: -
Feb 20, 2024
Initiates: Outperform
Price Target: $31
Current: $3.68
Upside: +742.39%
Nov 30, 2023
Initiates: Outperform
Price Target: $7
Current: $0.66
Upside: +968.54%
May 12, 2023
Downgrades: Market Perform
Price Target: $40
Current: $16.10
Upside: +148.52%
Feb 24, 2023
Downgrades: Underperform
Price Target: $111 → $93
Current: $27.75
Upside: +235.20%
Jan 23, 2023
Maintains: Outperform
Price Target: $86 → $84
Current: $9.74
Upside: +762.87%
Jan 23, 2023
Maintains: Market Perform
Price Target: $6 → $7
Current: $2.17
Upside: +222.58%
Jan 23, 2023
Maintains: Outperform
Price Target: $81 → $77
Current: $17.25
Upside: +346.38%
Jan 23, 2023
Maintains: Market Perform
Price Target: $144 → $143
Current: $316.25
Upside: -54.78%
Nov 14, 2022
Maintains: Market Perform
Price Target: $5 → $6
Current: $5.82
Upside: +3.09%
Nov 7, 2022
Maintains: Outperform
Price Target: $75 → $76
Current: $46.66
Upside: +62.90%
May 12, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $1.35
Upside: +2,418.52%
Jul 23, 2021
Maintains: Market Perform
Price Target: $50 → $20
Current: $2.49
Upside: +703.21%